ASAN FOUNDATION
- Country
- π°π·South Korea
- Ownership
- Private
- Established
- 1989-06-23
- Employees
- 501
- Market Cap
- -
- Website
- https://ails.amc.seoul.kr
Clinical Trials
1.3k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1147 trials with phase data)β’ Click on a phase to view related trials
Prediction of Postoperative Mortality in Patients Undergoing Non-cardiac Surgery: Development and Validation of the Surgical Mortality Model
- Conditions
- Mortality Prediction
- First Posted Date
- 2025-09-23
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 642377
- Registration Number
- NCT07188636
- Locations
- π°π·
Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Immunogenomic Dynamics and Biomarkers in Patients With Hepatocellular Carcinoma Receiving Immunotherapy
- Conditions
- Hepatocellular CarcinomaLiver Cancer
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT07186010
- Locations
- π°π·
Asan Medical Center, Seoul, Song-pa, South Korea
Prospective Multicenter Registry of Patients With Mitral Stenosis Undergoing Percutaneous Mitral Balloon Commissurotomy
- Conditions
- Mitral Stenosis
- First Posted Date
- 2025-09-16
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 400
- Registration Number
- NCT07175532
- Locations
- π°π·
Asan Medical Center, Seoul, South Korea
ThinkRadial: A Prospective Study of Transradial deTACE in HCC Patients
- Conditions
- Hepatocellular Carcinoma
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 38
- Registration Number
- NCT07160374
- Locations
- π°π·
Asan Medical Center, Seoul, Songpa-gu, South Korea
Allogeneic HCT Using Conditioning Regimen of BuFluATG for AML CR1
- Conditions
- Acute Myeloid Leukemia (AML)
- First Posted Date
- 2025-09-04
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 98
- Registration Number
- NCT07155382
- Locations
- π°π·
Asan Medical Center, Seoul, South Korea
- Prev
- 1
- 2
- 3
- 4
- 5
- 113
- Next
News
Daewoong Pharmaceutical Advances Phase 2 Trial of Novel IPF Drug Bersiporocin with Diverse Patient Population
Daewoong Pharmaceutical presented interim Phase 2 results for Bersiporocin (DWN12088), a first-in-class oral antifibrotic drug targeting idiopathic pulmonary fibrosis, at the 2025 American Thoracic Society International Conference.
Huonslab Completes Enrollment in Phase 1 Trial for Recombinant Hyaluronidase, Eyes 2025 Regulatory Filing
Huonslab has completed patient enrollment in its pivotal Phase 1 clinical trial of HLB3-002 (Hydizymeβ’), a recombinant human hyaluronidase, with 243 healthy volunteers across four leading South Korean medical centers.
Early Hepatitis B Treatment with Vemlidy Shows Promise in Preventing Liver Cancer
Interim analysis of the ATTENTION trial suggests early treatment with Vemlidy (tenofovir alafenamide) significantly reduces liver-related events in hepatitis B patients.
ROTEM-Guided TXA Administration vs. Preemptive TXA for Bleeding in Cardiovascular Surgery: A Randomized Trial
A multi-center, double-blind, randomized trial is underway to compare ROTEM-guided tranexamic acid (TXA) administration with preemptive TXA in cardiovascular surgery patients.
Fecal Microbiota Transplants Show Promise in Overcoming Immunotherapy Resistance in GI Cancers
A South Korean study suggests fecal microbiota transplants (FMTs) may enhance immunotherapy efficacy in gastrointestinal (GI) cancer patients resistant to anti-PD-1 drugs.
Flexible Antiplatelet Management Safe After Drug-Eluting Stent Implantation
A recent trial suggests that discontinuing antiplatelet therapy around non-cardiac surgery is non-inferior to continuing aspirin monotherapy for patients with prior drug-eluting stent (DES) implantation.